The Eastern Cooperative Oncology Group (ECOG), one of the largest clinical cooperative groups in the country, proposes to continue serving as a Research Base for the 21 applicant programs comprising its Community Clinical Oncology Program (CCOP). The ECOG Research Base has recently undergone significant evolution to improve and expand its cancer prevention and control research capacity. In this proposal, five years of additional support is requested to continue this on-going process of improving and expanding the ECOG Research Base to better serve the needs of the CCOP programs. To meet its on-going responsibilities as a Research Base, ECOG will focus its efforts on the following: l) Continue to expand and strengthen its cancer prevention, control and treatment research capacity within the CCOP programs and other ECOG participants; 2) Continue to stimulate the development of state-of-the-science NCI- approved cancer prevention and control intervention protocols to the CCOP programs and other ECOG participants, including research protocols that specifically target women and under-served populations; 3) Continue to provide the network of community-based physicians and hospitals in ECOG with the necessary services and resources to support state-of-the-science cancer research in the community, including protocol development, patient accrual, data management and quality control, and analytic support; 4) Continue to provide a wide variety of training workshops for the CCOPs, including minority CCOPs, in patient accrual and data management, as well as ECOG, NCI, and FDA procedures and regulations; 5) Continue to provide the CCOPs with the leadership and administrative services described above through the ECOG Operations Office and the ECOG Statistical Center, and continue the on-going process of making these key organizational units more responsive to the needs of the CCOP program; 6) Continue to pursue an aggressive program of community-based cancer prevention and control research by being responsive to NCI requests and priority areas in this regard; 7) Continue to fulfill the mandated responsibilities of the Research Base in evaluating and monitoring the activities of the CCOPs through site visits, meetings, progress reports and performance reviews.
Related Clinical Trials Conducted by the group:
| 1 | Diagnostic Study to Correlate Histopathology, Immunochemistry, and Quantitative Radiology With Outcome in Patients With Early Stage Nonseminomatous Germ Cell Tumor of the Testis | |
| 2 | Genetic Mapping of Interactive Susceptibility Loci in Patients and Siblings with Breast, Colon, Lung, or Prostate Cancer | |
| 3 | Phase I Study of Amifostine and High-Dose Melphalan in Patients With Primary Systemic Amyloidosis Undergoing Autologous Peripheral Blood Stem Cell Transplantation | |
| 4 | Phase II Pilot Study of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia | |
| 5 | Phase II Randomized Study of Anastrozole and Gefitinib Versus Fulvestrant and Gefitinib in Postmenopausal Women With Recurrent or Metastatic Hormone Receptor-Positive Breast Cancer | |
| 6 | Phase II Randomized Study of BAY 43-9006 in Patients With Refractory Non-Small Cell Lung Cancer | |
| 7 | Phase II Randomized Study of Gemcitabine and Radiotherapy Versus Gemcitabine, Fluorouracil, and Cisplatin Followed By Radiotherapy and Fluorouracil in Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the Pancreas | |
| 8 | Phase II Randomized Study of Irinotecan and Docetaxel With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Pancreas | |
| 9 | Phase II Randomized Study of Multi-Epitope Vaccination With Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Patients With Metastatic Melanoma | |
| 10 | Phase II Randomized Study of Radiotherapy With Pre- and Post-Operative Cisplatin Plus Paclitaxel Versus Cisplatin Plus Irinotecan in Patients With Operable Adenocarcinoma of the Esophagus or Gastroesophageal Junction | |
| 11 | Phase II Randomized Study of Topotecan, Cisplatin, and Etoposide and Irinotecan, Cisplatin, and Etoposide in Patients With Extensive Stage Small Cell Lung Cancer | |
| 12 | Phase II Study of Bortezomib in Patients With Hepatocellular Carcinoma | |
| 13 | Phase II Study of Rituximab and CHOP Chemotherapy Comprising Prednisone, Cyclophosphamide, Doxorubicin, and Vincristine Followed By Yttrium Y 90 Ibritumomab Tiuxetan (Yttrium Y 90 Zevalin??A?) in Patients With Previously Untreated Mantle Cell Lymphoma | |
| 14 | Phase II Study of 3-AP (Triapine) and Gemcitabine as Second-Line Treatment in Patients With Progressive or Recurrent Non-Small Cell Lung Cancer | |
| 15 | Phase II Study of Alemtuzumab (Monoclonal Antibody CD52; Campath-1H) and Peripheral Blood Stem Cell Transplantation in Patients With Chronic Lymphocytic Leukemia | |
| 16 | Phase II Study of Amifostine and High-Dose Melphalan Followed By Autologous Hematopoietic Stem Cell Transplantation in Patients With Multiple Myeloma | |
| 17 | Phase II Study of Atrasentan in Patients With Locally Recurrent or Metastatic Renal Cell Carcinoma | |
| 18 | Phase II Study of Bortezomib Followed By the Addition of Doxorubicin at Disease Progression in Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma of the Head and Neck | |
| 19 | Phase II Study of Bortezomib in Patients With Newly Diagnosed High-Risk Stage III Multiple Myeloma | |
| 20 | Phase II Study of Capecitabine and Tipifarnib in Women With Taxane-Resistant Metastatic Breast Cancer | |
| 21 | Phase II Study of Carboplatin and Paclitaxel in Patients With Advanced Thymoma or Thymic Carcinoma | |
| 22 | Phase II Study of Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma or Neuroendocrine Hepatic Metastases | |
| 23 | Phase II Study of Cisplatin, Etoposide, and Bevacizumab in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer | |
| 24 | Phase II Study of Cyclosporine in Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma | |
| 25 | Phase II Study of Dalteparin and Conventional Radiotherapy in Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme | |
| 26 | Phase II Study of Doxorubicin HCl Liposome and Docetaxel With or Without Trastuzumab (Herceptin??A?A?) in Women With Metastatic Breast Cancer | |
| 27 | Phase II Study of Doxorubicin and Gemcitabine in Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Cancer With Sarcomatoid Features | |
| 28 | Phase II Study of Gefitinib in Patients With Advanced Unresectable Hepatocellular Carcinoma | |
| 29 | Phase II Study of High-Dose Methotrexate and Leucovorin Calcium Followed By Radiotherapy in Patients With Newly Diagnosed Glioblastoma Multiforme | |
| 30 | Phase II Study of Interferon alfa, Isotretinoin, and Paclitaxel in Patients With Recurrent Small Cell Lung Cancer | |
| 31 | Phase II Study of Irinotecan and Docetaxel in Patients With Metastatic or Locally Recurrent Head and Neck Cancer | |
| 32 | Phase II Study of Ixabepilone in Patients With Metastatic Hormone-Refractory Adenocarcinoma of the Prostate | |
| 33 | Phase II Study of Ixabepilone in Patients With Advanced Carcinoma of the Urothelium | |
| 34 | Phase II Study of Low-Dose PEG-Interferon alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor | |
| 35 | Phase II Study of Methotrexate With or Without Cyclophosphamide in Patients with Large Granular Lymphocytic Leukemia | |
| 36 | Phase II Study of Minimally Invasive Esophagectomy in Patients With High-Grade Dysplasia of the Esophagus or Stage I-III Esophageal Cancer | |
| 37 | Phase II Study of Neoadjuvant Erlotinib in Patients With Early-Stage Operable Non-Small Cell Lung Cancer | |
| 38 | Phase II Study of Neoadjuvant Induction Therapy Comprising Cetuximab, Paclitaxel, and Carboplatin Followed By Chemoradiotherapy Comprising Cetuximab, Paclitaxel, Carboplatin, and Radiotherapy in Patients With Stage III or IV Operable Squamous Cell Cancer of the Head and Neck | |
| 39 | Phase II Study of Paclitaxel and Carboplatin in Patients With Locally Advanced or Metastatic Collecting Duct Renal Cell Cancer | |
| 40 | Phase II Study of Pemetrexed Disodium and Gemcitabine in Patients With Advanced Cancer of the Urothelium | |
| 41 | Phase II Study of Pentostatin, Cyclophosphamide, and Rituximab Followed By Alemtuzumab in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia | |
| 42 | Phase II Study of Perifosine in Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer | |
| 43 | Phase II Study of Preradiation Combination Chemotherapy in Adults with Poor-Risk Medulloblastoma, Peripheral Primitive Neuroectodermal Tumor, or Disseminated Ependymoma | |
| 44 | Phase II Study of Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, and Vincristine Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Patients With Stage I or II CD20-Positive Diffuse Large Cell Lymphoma | |
| 45 | Phase II Study of Salvage Cellular Immunotherapy With Donor Lymphocyte Infusions in Patients With Recurrent Multiple Myeloma After Allogeneic Bone Marrow Transplantation from an HLA-Matched Sibling Donor | |
| 46 | Phase II Study of Temozolomide and Whole Brain Radiotherapy in Patients With Brain Metastasis Secondary to Non-Small Cell Lung Cancer | |
| 47 | Phase II Study of Trastuzumab (Herceptin??A?), Ixabepilone, and Carboplatin in Patients With HER2/neu-Positive Metastatic Breast Cancer | |
| 48 | Phase II Study of a Nonmyeloablative Conditioning Regimen Followed By Allogeneic Bone Marrow Transplantation in Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma | |
| 49 | Phase II Study of a Reduced-Intensity Preparative Regimen With Allogeneic Bone Marrow Transplantation in Patients With Myelodysplastic Syndromes | |
| 50 | Phase III Randomized Adjuvant Study of High-Dose Interferon alfa-2b Therapy in Patients With Stage II or III Melanoma | |
| 51 | Phase III Randomized Chemoprevention Study of Selenium in Participants With Previously Resected Stage I Non-Small Cell Lung Cancer | |
| 52 | Phase III Randomized Study of Adjuvant Irinotecan, Fluorouracil, and Leucovorin Calcium Versus Oxaliplatin, Fluorouracil, and Leucovorin Calcium Versus Fluorouracil and Leucovorin Calcium in Patients With Stage II or III Rectal Cancer Receiving Combined Radiotherapy and Fluorouracil Either Preoperatively or Postoperatively | |
| 53 | Phase III Randomized Study of Adjuvant Isotretinoin, Interferon alfa, and Vitamin E in Patients With Stage III or IV Squamous Cell Carcinoma of the Head and Neck | |
| 54 | Phase III Randomized Study of Allogeneic or Autologous Stem Cell Transplantation Versus Conventional Consolidation and Maintenance Chemotherapy in Patients With Acute Lymphoblastic Leukemia in First Remission | |
| 55 | Phase III Randomized Study of Carboplatin, Paclitaxel, and Chemoradiotherapy With or Without Thalidomide in Patients With Stage III Non-Small Cell Lung Cancer | |
| 56 | Phase III Randomized Study of Daunorubicin and Cytarabine With or Without Gemtuzumab Ozogamicin Followed By Autologous Hematopoietic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia | |
| 57 | Phase III Randomized Study of Daunorubicin and Cytarabine With or Without Zosuquidar Trihydrochloride in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts (RAEB) in Transformation, or High-Risk RAEB | |
| 58 | Phase III Randomized Study of Docetaxel With or Without Gefitinib in Patients With Metastatic or Locally Recurrent Squamous Cell Carcinoma of the Head and Neck | |
| 59 | Phase III Randomized Study of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) Versus Doxorubicin, Vinblastine, Vincristine, Bleomycin, Mechlorethamine, Etoposide, and Prednisone (Stanford V) With or Without Radiotherapy in Patients With Locally Extensive or Advanced Hodgkin's Lymphoma | |
| 60 | Phase III Randomized Study of Epoetin alfa With or Without Dexamethasone for the Treatment of Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer | |
| 61 | Phase III Randomized Study of Gemcitabine With or Without Radiotherapy in Patients With Locally Advanced, Unresectable Pancreatic Cancer | |
| 62 | Phase III Randomized Study of Interferon alfa-2b With or Without Thalidomide in Patients With Previously Untreated Metastatic or Unresectable Renal Cell Carcinoma | |
| 63 | Phase III Randomized Study of Prolonged Infusion Gemcitabine With Versus Without Oxaliplatin Versus Standard Infusion Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Cancer | |
| 64 | Phase III Randomized Study of Rituximab in Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma | |
| 65 | Phase III Randomized Study of Sargramostim (GM-CSF) and Peptide Vaccination Comprised of Tyrosinase:368-376, gp100:209-217 (210M) Antigen, and MART-1:27-35 Peptide Versus Peptide Vaccination Alone Versus GM-CSF Alone Versus Placebo in Patients With Locally Advanced or Metastatic Melanoma | |
| 66 | Phase III Randomized Study of Second-Line Hormonal Therapy (Ketoconazole and Hydrocortisone) Versus Combination Chemotherapy (Docetaxel and Estramustine) in Asymptomatic Patients With Prostate Cancer and a Rising Prostate-Specific Antigen After Androgen Suppression | |
| 67 | Pilot Study of Erlotinib in Patients With Stage IIIB or IV or Recurrent Non-Small Cell Lung Cancer | |
| 68 | Randomized Pilot Study to Evaluate Educational Intervention and Behavioral Skills Training for Pain Control in Patients With Recurrent or Metastatic Breast or Prostate Cancer | |
This project is coded as follows:
Type of Cancer Research Codes:
- Education and Communication
- Resources and Infrastructure Related to Cancer Control, Survivorship, and Outcomes Research
Type of Cancer Codes:
- Bladder Cancer
- Blood Cancer
- Bone Marrow Transplantation
- Brain Tumor
- Breast Cancer
- Cervical Cancer
- Colon and Rectal Cancer
- Esophageal Cancer
- Gastrointestinal Tract
- Genital System, Female
- Genital System, Male
- Head and Neck Cancer
- Hodgkin's Disease
- Kidney Cancer
- Leukemia
- Lung Cancer
- Melanoma
- Myeloma
- Nervous System
- Non-Hodgkin's Lymphoma
- Pancreatic Cancer
- Prostate Cancer
- Respiratory System
- Skin Cancer
- Thymoma, Malignant
- Urinary System
E-Mail this page
Define terms on this page
View related clinical trials conducted by this group